Navigation Links
Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Date:6/2/2010

s or implied discussions regarding potential new indications or labeling for Afinitor or regarding potential future revenues from Afinitor. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Afinitor to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Afinitor will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that Afinitor will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Afinitor could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Fruit Street ... secured an initial seed round of funding. ... was led by a series of individual investors, the ... whom participated in the initial round are; Houston ... Medical Center Urologist Stacy Childs, Rapha Family Medicine Practice ...
(Date:9/18/2014)... Pharma IQ, after huge demand ... Countdown calendar to cover the years 2014 - 2018 ... shows the serialisation requirements around the globe and the ... For companies dealing with international markets, serialisation ... they will have to comply with new regulations coming ...
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   (NYSE: ... Simbionix RobotiX Mentor™ , a new robotic surgery skills ... first time at the ERUS exhibition in Amsterdam, ... #7). Robotic-assisted minimally invasive surgery represents a growing ... the needs for training for robotic surgery has increased, and ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 23D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3
... Biomerix Corporation announced today that it has received ... mesh allowing for the marketing of REVIVE in all ... clearance from the U.S. Food and Drug Administration (FDA) ... the Biomerix Biomaterial™, a proprietary, biointegrative synthetic tissue scaffold. ...
... ANNAPOLIS, Md., Jan. 24, 2011 PharmAthene, Inc. (NYSE Amex: ... the Delaware Court of Chancery, which commenced January 3, 2011, ... this past Friday, January 21, 2011. The Company anticipates that ... in front of the court will be complete by the ...
Cached Medicine Technology:Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh 2PharmAthene Provides Update on Litigation With SIGA Technologies 2
(Date:9/18/2014)... Luis Obispo, CA (PRWEB) September 18, 2014 ... Bootie introduced their newest, patent pending bunion splint to ... As one loyalist, Rosa, wrote: "I was absolutely delighted. It ... I honestly forget I am wearing them. THANK YOU FOR ... recently introduced design by saying, "The hole used to slip ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. ... a common antidepressant can quickly alter the way brain cells ... reported online Sept. 18 in Current Biology , ... widely prescribed antidepressants. Experts said the hope is to eventually ... to benefit from a drug -- and which people would ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading ... and co-founder John Cassimatis was named as one ... 2014, recognizing the region’s top healthcare and life ... of the year. , The Innovation Awards celebrate ... continue to shape the medical industry in Greater ...
(Date:9/18/2014)... microbes -- don,t worry, it,s a good thing! As ... microbes are bad. Many active enzymes and bacteria are ... as an important part of our digestive system or ... albicans , an opportunistic yeast pathogen and model organism ... healthy personal ecosystem. However, when our immune system is ...
(Date:9/18/2014)... The effect of guidelines recommending that elderly men should ... minimal at best," according to a new study led ... as a research letter online in JAMA Internal ... prostate-specific antigen to test for prostate cancer., "We ... the routine screening of elderly men in particular has ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2
... Analytical, based in Ames, IA will reveal the latest results ... system. This instrument rapidly identifies microorganisms in less ... The generated fingerprint when compared to a database of ... strain typing and tracking.Because of its ease of use and ...
... 2009, the United States District Court for the Southern ... previously disclosed antitrust lawsuit filed by Pioneer Valley Casket ... casket retailers against Batesville Casket Company, Inc., a wholly ... )The Pioneer Valley plaintiffs agreed to dismiss their complaint ...
... Inc. (NYSE: DVA ) announced that the United ... has informed the company that it has completed its investigation ... was first issued a formal subpoena in October 2004 and ... against the company, no fines were assessed and no mandatory ...
... A new survey from Noblis Health Innovation, a ... context of the current economic crisis, nearly a third of hospitals ... Conducted in April 2009, the affiliation study is the first in ... Noblis Insights Panel , a collection of more than 150 leading ...
... make that dream so real, goes a popular song. Now ... to perform an essential form of DNA repair. , Prof. ... been studying DNA repair for some two decades: ,Considering that ... a day by radiation, pollutants and harmful chemicals produced within ...
... Cancer Screenings And Education about Skin Cancer PreventionSKILLMAN, N.J., ... Johnson Consumer Companies, Inc., announces its second year of ... Skin" tour. The free skin cancer screening tour ... New York City,s Grand Central Terminal, and will visit ...
Cached Medicine News:Health News:Advanced Analytical Reveals New Platform for Rapid Genotypic Identification of Microorganisms at ASM 2009 2Health News:Federal District Judge Dismisses Antitrust Lawsuit Against Batesville Casket Company 2Health News:Noblis Insights Panel Finds Growing Interest in Hospital Affiliation as a Strategic Response to Challenging Market Conditions 2Health News:Noblis Insights Panel Finds Growing Interest in Hospital Affiliation as a Strategic Response to Challenging Market Conditions 3Health News:Stopgap DNA repair needs a second step 2Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 2Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 3Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 4
Span Diagnostics Limited...
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
DiaMed OptiMAL-IT is an immuno-chromatographic test, using monoclonal antibodies against the metabolic enzyme pLDH (parasite lactate dehydrogenase) of Plasmodium spp. These Mabs are classified in t...
Core Malaria Pf is a rapid self performing, qualitative, two site sandwich immunoassay for the determination of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples...
Medicine Products: